Brainstorm Cell Therapeutics (BCLI) Price & Analysis

Compare

563 Followers

BCLI Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.72 - $6.93

Previous CloseN/A

Volume34.73K

Average Volume (3M)2.39M

Market Cap

$8.73M

Enterprise Value$901.44M

Total Cash (Recent Filing)$187.00K

Total Debt (Recent Filing)$720.00K

Price to Earnings (P/E)―

Beta1.73

Next Earnings

Aug 18, 2025

EPS Estimate

-0.37

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.45

Shares Outstanding7,938,876

10 Day Avg. Volume431,634

30 Day Avg. Volume2,390,283

Financial Highlights & Ratios

PEG Ratio12.68

Price to Book (P/B)-297.88

Price to Sales (P/S)0.00

P/FCF Ratio-46.42

Enterprise Value/Market Cap103.23

Enterprise Value/Revenue876.04

Enterprise Value/Gross Profit-1.42K

Enterprise Value/Ebitda-14.69

Forecast

1Y Price Target

$6.00

Price Target Upside445.45% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Brainstorm Cell Therapeutics News

See All News >

Bulls Say, Bears Say

Bulls Say

FDA ClearanceFDA clearance for the upcoming P3b (ENDURANCE) study in amyotrophic lateral sclerosis (ALS) announced, positioning BrainStorm to acquire funds for the trial, including non-dilutive sources like a $15M grant under review.

Manufacturing CollaborationThe strategic collaboration with Minaris Advanced Therapies enhances US-based manufacturing capabilities and brings the scalability needed for NurOwn's complex autologous cell therapy.

Therapeutic ImpactNurOwn is the most advanced therapy in the ALS space, is safe, and has a history of positive therapeutic impact, making the trial crucial for patients and caregivers.

Bears Say

Macroeconomic FactorsPre-revenue Biotech is particularly susceptible to macroeconomic factors due to its reliance on capital and inherent uncertainty.

Market ConditionsDifficult market conditions, particularly for small/micro-cap stocks, and economic uncertainty continue to pressure broader markets.

Valuation ChallengesValuations across much of the Biotech space have continued to pullback and reset, with reductions in price targets for multiple stocks.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

9.99% Insiders

0.98% Mutual Funds

13.21% Other Institutional Investors

75.49% Public Companies and Individual Investors

Detailed Ownership Overview >

BCLI FAQ

What was Brainstorm Cell Therapeutics’s price range in the past 12 months?

Brainstorm Cell Therapeutics lowest stock price was $0.72 and its highest was $6.93 in the past 12 months.

What is Brainstorm Cell Therapeutics’s market cap?

Brainstorm Cell Therapeutics’s market cap is $8.73M.

When is Brainstorm Cell Therapeutics’s upcoming earnings report date?

Brainstorm Cell Therapeutics’s upcoming earnings report date is Aug 18, 2025 which is in 63 days.

How were Brainstorm Cell Therapeutics’s earnings last quarter?

Brainstorm Cell Therapeutics released its earnings results on May 16, 2025. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.45.

Is Brainstorm Cell Therapeutics overvalued?

According to Wall Street analysts Brainstorm Cell Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Brainstorm Cell Therapeutics pay dividends?

Brainstorm Cell Therapeutics does not currently pay dividends.

What is Brainstorm Cell Therapeutics’s EPS estimate?

Brainstorm Cell Therapeutics’s EPS estimate is -0.37.

How many shares outstanding does Brainstorm Cell Therapeutics have?

Brainstorm Cell Therapeutics has 7,938,876 shares outstanding.

What happened to Brainstorm Cell Therapeutics’s price movement after its last earnings report?

Brainstorm Cell Therapeutics reported an EPS of -$0.45 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 13.793%.

Which hedge fund is a major shareholder of Brainstorm Cell Therapeutics?

Currently, no hedge funds are holding shares in BCLI

Company Description

Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics (BCLI) is a biotechnology company focused on the development of innovative cellular therapies for the treatment of neurodegenerative diseases. Operating primarily in the biotechnology sector, the company's core product is NurOwn, an autologous cellular therapy that utilizes mesenchymal stem cells to deliver neurotrophic factors directly to the site of damage in the nervous system. Brainstorm is committed to providing transformative solutions that improve patient outcomes and address unmet medical needs in conditions such as amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

BCLI Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted significant progress in regulatory clearance and clinical trial preparations for NurOwn, alongside promising biomarker research and development in the exosome program. However, financial constraints and the need for funding to initiate the trial were notable challenges.Read More>

BCLI Stock 12 Month Forecast

Average Price Target

$6.00

▲(445.45%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","45":"$45","11.25":"$11.25","22.5":"$22.5","33.75":"$33.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,11.25,22.5,33.75,45],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"Jul<br/>2024","9":"Oct<br/>2024","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.16,1.5323076923076921,1.9046153846153846,2.276923076923077,2.649230769230769,3.0215384615384613,3.3938461538461535,3.7661538461538457,4.138461538461538,4.51076923076923,4.883076923076922,5.2553846153846155,5.627692307692308,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.16,1.5323076923076921,1.9046153846153846,2.276923076923077,2.649230769230769,3.0215384615384613,3.3938461538461535,3.7661538461538457,4.138461538461538,4.51076923076923,4.883076923076922,5.2553846153846155,5.627692307692308,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.16,1.5323076923076921,1.9046153846153846,2.276923076923077,2.649230769230769,3.0215384615384613,3.3938461538461535,3.7661538461538457,4.138461538461538,4.51076923076923,4.883076923076922,5.2553846153846155,5.627692307692308,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.6,"date":1672531200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.6,"date":1677628800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.1,"date":1685577600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.1,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.45,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.9,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.36,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.01,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.63,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.25,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.71,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >